Quick Answer
CASI Pharmaceuticals, Inc. reported Revenue (ASC 606) of $28.54 million for fiscal year 2024.
CASI Pharmaceuticals, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $28.54M | -15.8% |
| 2023 | $33.88M | -11.0% |
| 2022 | $38.05M | +26.7% |
| 2021 | $30.02M | +100.1% |
| 2020 | $15.00M | — |
- CASI Pharmaceuticals, Inc. showed a decrease of -15.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2024 period, CASI Pharmaceuticals, Inc.’s revenue (asc 606) has grown by 90.2% (from $15.00 million to $28.54 million).
- The most recent figure is from CASI Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: